Strategic funders Purespring is backed by high-profile investors including Syncona and Sofinnova Partners with a recent $105M Series B, indicating strong financial backing and potential for large-scale collaboration or co-development opportunities with primary investors and portfolio companies.

Clinical focus As a first-in-class podocyte-targeting AAV gene therapy company focused on kidney diseases, Purespring presents opportunities for partnerships in nephrology clinical trials, companion diagnostics, and CRO/CMO services aligned with precision nephrology and glomerular disease research.

Key partnerships Existing collaboration with Andelyn Biosciences as a CDMO partner suggests a receptive channel for expanding manufacturing, vector production, and process development services to support scaling gene therapies for renal indications.

Clinical momentum Ongoing Phase I/II study of PS-002 with updates on study design and real world evidence presentations indicate demand for clinical operations, patient recruitment, data capture, and patient engagement strategies to accelerate trials and regulatory milestones.

Industry presence Active participation in major conferences and events signals awareness needs for investor relations, enterprise partnerships, and business development outreach to biopharma companies pursuing genetic medicines, gene therapy manufacturing, or renal disease therapeutics.